Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS

[1]  M. Bauer,et al.  Quantification of mRNA degradation as possible indicator of postmortem interval--a pilot study. , 2003, Legal medicine.

[2]  L. Griffiths,et al.  Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. , 2003, Brain research. Molecular brain research.

[3]  N. Cairns,et al.  Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. , 2003, Brain research. Molecular brain research.

[4]  R. Reynolds,et al.  Molecular Changes in Normal Appearing White Matter in Multiple Sclerosis are Characteristic of Neuroprotective Mechanisms Against Hypoxic Insult , 2003, Brain pathology.

[5]  Javed Khan,et al.  Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. , 2003, Human molecular genetics.

[6]  Murali Ramanathan,et al.  Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.

[7]  C. Polman,et al.  Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis , 2003, Annals of neurology.

[8]  K. Selmaj,et al.  cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. , 2003, Brain : a journal of neurology.

[9]  R. Ledeen,et al.  Fatty acid synthesizing enzymes intrinsic to myelin. , 2003, Brain research. Molecular brain research.

[10]  D. Heinegård,et al.  Comment on "The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease" , 2003, Science.

[11]  B. Trapp,et al.  Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease , 2003, Journal of the Neurological Sciences.

[12]  Kenneth J. Smith,et al.  Blockers of sodium and calcium entry protect axons from nitric oxide‐mediated degeneration , 2003, Annals of neurology.

[13]  M Rovaris,et al.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.

[14]  F. Barkhof,et al.  Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy , 2003 .

[15]  K. Jellinger,et al.  Preferential Loss of Myelin‐Associated Glycoprotein Reflects Hypoxia‐Like White Matter Damage in Stroke and Inflammatory Brain Diseases , 2003, Journal of neuropathology and experimental neurology.

[16]  G. Ebers,et al.  An array of sunshine in multiple sclerosis. , 2002, The New England journal of medicine.

[17]  G. Rosenberg.  Matrix metalloproteinases in neuroinflammation , 2002, Glia.

[18]  S. Cook,et al.  Caspase-1 expression in multiple sclerosis plaques and cultured glial cells , 2002, Journal of the Neurological Sciences.

[19]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[20]  A. Riccio,et al.  Apoptosis, Axonal Growth Defects, and Degeneration of Peripheral Neurons in Mice Lacking CREB , 2002, Neuron.

[21]  K. Unsicker,et al.  TGF-β and the regulation of neuron survival and death , 2002, Journal of Physiology-Paris.

[22]  David H. Miller,et al.  The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis , 2002, Journal of Neurology.

[23]  M. Huentelman,et al.  Characterization of mitotic neurons derived from adult rat hypothalamus and brain stem. , 2002, Journal of neurophysiology.

[24]  M. Sharief,et al.  Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability , 2002, Journal of Neuroimmunology.

[25]  S. Ludwin,et al.  Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions , 2001, Journal of Neuroimmunology.

[26]  Jorge R. Oksenberg,et al.  The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease , 2001, Science.

[27]  R. Kinkel,et al.  Axonal loss in normal-appearing white matter in a patient with acute MS , 2001, Neurology.

[28]  L. Steinman.  Gene microarrays and experimental demyelinating disease: a tool to enhance serendipity. , 2001, Brain : a journal of neurology.

[29]  L. Kappos,et al.  The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. , 2001, Brain : a journal of neurology.

[30]  Randomized controlled trial of interferon- beta-1a in secondary progressive MS , 2001, Neurology.

[31]  D. Li,et al.  Randomized controlled trial of interferon-beta-1a in secondary progressive MS , 2001, Neurology.

[32]  H. Lassmann,et al.  Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. , 2001, Brain : a journal of neurology.

[33]  V. Kaartinen,et al.  TGF-β3-induced Palatogenesis Requires Matrix Metalloproteinases , 2001 .

[34]  Kenneth J. Smith,et al.  Electrically active axons degenerate when exposed to nitric oxide , 2001, Annals of neurology.

[35]  C. Lucchinetti,et al.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.

[36]  S. Baranzini,et al.  Transcriptional Analysis of Multiple Sclerosis Brain Lesions Reveals a Complex Pattern of Cytokine Expression1 , 2000, The Journal of Immunology.

[37]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[38]  G J Barker,et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.

[39]  J. Sotelo,et al.  Neurofilament mRNAs are present and translated in the normal and severed sciatic nerve , 2000, Journal of neuroscience research.

[40]  G J Barker,et al.  The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. , 2000, Brain : a journal of neurology.

[41]  R. Derynck,et al.  Transcriptional Regulation of the Transforming Growth Factor-β-inducible Mouse Germ Line Ig α Constant Region Gene by Functional Cooperation of Smad, CREB, and AML Family Members* , 2000, The Journal of Biological Chemistry.

[42]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[43]  C. D. DE GROOT,et al.  Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS , 2000, Neuropathology and applied neurobiology.

[44]  S. Baranzini,et al.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. , 1999, Journal of immunology.

[45]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[46]  J. Trent,et al.  Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays , 1999 .

[47]  J. Udupa,et al.  Familial multiple sclerosis: volumetric assessment in clinically symptomatic and asymptomatic individuals , 1999, Multiple sclerosis.

[48]  R. Armstrong,et al.  Intracellular signals and cytoskeletal elements involved in oligodendrocyte progenitor migration , 1999, Glia.

[49]  A. Gloster,et al.  Early induction of Tα1 α‐tubulin transcription in neurons of the developing nervous system , 1999 .

[50]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[51]  Kenneth J. Smith,et al.  Demyelination: The Role of Reactive Oxygen and Nitrogen Species , 1999, Brain pathology.

[52]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[54]  M Filippi,et al.  Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis , 1998, Annals of neurology.

[55]  T. Olsson,et al.  Genetic influence on disease course and cytokine response in relapsing experimental allergic encephalomyelitis. , 1998, International immunology.

[56]  K. Becker,et al.  Analysis of a sequenced cDNA library from multiple sclerosis lesions , 1997, Journal of Neuroimmunology.

[57]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[58]  L. Santambrogio,et al.  Staphylococcal enterotoxin B and tumor‐necrosis factor‐α‐induced relapses of experimental allergic encephalomyelitis: Protection by transforming growth factor‐β and interleukin‐10 , 1995, European journal of immunology.

[59]  Y. Ohyagi,et al.  Hemoglobin as a novel protein developmentally regulated in neurons , 1994, Brain Research.

[60]  R I Grossman,et al.  Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. , 1992, Radiology.

[61]  E. Shooter,et al.  Identification of transcriptionally regulated genes after sciatic nerve injury , 1991, Journal of neuroscience research.

[62]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[63]  H. Lassmann,et al.  Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG) , 1987, Journal of Neuroimmunology.

[64]  K. Suzuki,et al.  Myelin in multiple sclerosis. Composition of myelin from normal-appearing white matter. , 1973, Archives of neurology.

[65]  Murali Ramanathan,et al.  Genomic effects of IFN-beta in multiple sclerosis patients. , 2003, Journal of immunology.

[66]  K. Unsicker,et al.  TGF-beta and the regulation of neuron survival and death. , 2002, Journal of physiology, Paris.

[67]  V. Kaartinen,et al.  TGF-beta3-induced palatogenesis requires matrix metalloproteinases. , 2001, Molecular biology of the cell.

[68]  R. Derynck,et al.  Transcriptional regulation of the transforming growth factor-beta -inducible mouse germ line Ig alpha constant region gene by functional cooperation of Smad, CREB, and AML family members. , 2000, The Journal of biological chemistry.

[69]  A. Thompson,et al.  The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis , 2000 .

[70]  Antoine de Saizieu,et al.  Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays , 1998, Nature Biotechnology.

[71]  D. Lockhart,et al.  Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.

[72]  P. Sarkar,et al.  Regulation of actin and tubulin gene expression by thyroid hormone during rat brain development. , 1996, Brain research. Molecular brain research.

[73]  Journal of Neuroimmunology , 2022 .